Lack of p53 or mismatch repair (MR) function and scarce cell proliferation are commonly associated with tumor cell resistance to antineoplastic agents. Recently, inhibition of poly(ADP-ribose) polymerase (PARP) has been considered as a tool to overcome resistance of MR-deficient tumors to methylating agents. In the present study we demonstrated that infection with p53 expressing adenovirus (Ad-p53), enhances chemosensitivity of MR-deficient tumor cell lines to the methylating agent temozolomide (TZM), either used as single agent or, more efficiently, when combined with PARP inhibitor. Moreover, the association of Ad-p53 with drug treatment induced a more pronounced growth inhibitory effect than that provoked by Ad-p53 infection only. Cells, growth arrested by p53 transduction, and then subsequently exposed to the drugs, were still highly susceptible to cytotoxicity induced by TZM and PARP inhibitor. The results suggested that this drug combination might be effective even in nonproliferating tumor cells. It is conceivable to envisage future possible strategies to enhance cytostatic or cytotoxic effects induced by Ad-p53, based on the use of TZM, alone or combined with PARP inhibitor for the therapy of resistant tumors. Cell Death and Differentiation (2001) 8, 457 ± 469.
Introduction
A number of studies demonstrated that the p53 tumor suppressor gene plays a major role in apoptosis/growth arrest or DNA repair, in response to DNA damage, including that deriving from chemotherapeutic agents. 1 ± 4 Actually, genetic abnormalities resulting in loss of p53 function can contribute to the frequent clinical resistance of solid tumors to chemotherapeutic treatments. In addition, it has been observed that wild-type p53 overexpression in cancer cells can directly induce cells to undergo apoptosis and/or growth arrest. 5 ± 9 These findings provided the rational basis for gene transfer based techniques aimed at restoring or enhancing the wild-type p53 function, thus providing additional devices for cancer control.
Mutation of the p53 gene is the most common genetic alteration 10 detected in human solid tumors (e.g. 70% in colorectal cancers). 11 Moreover, although mutations in the p53 tumor suppressor gene are not common in hematological malignancies, they have been frequently detected in therapy-related acute myeloid leukemias (i.e. 39%). 12, 13 In any case, p53 mutations are associated with low complete remission rate, early relapse and poor survival. 14, 15 Genetic abnormalities responsible for drug resistance also involve genes encoding for components of the DNA mismatch repair (MR), which plays an important role in maintaining genomic stability. 16 Defects in MR function result in tumor cell resistance to O 6 -methylating compounds and to a number of antineoplastic agents with different mechanisms of action, such as 6-thioguanine, cisplatin and doxorubicin. 17 A functional MR is required for the triggering of the apoptotic process in response to O 6 -methylguanine DNA adducts. 18 In contrast, tumor cell susceptibility to damage derived from methyl adducts generated at DNA sites different from O 6 -guanine does not require the presence of a functional MR. 19, 20 However, these DNA adducts are efficiently removed by the base excision repair (BER) and include N 3 -methyladenine, that is generated at low levels in the DNA by the methylating agents commonly used in the clinic, such as dacarbazine or temozolomide (TZM). 21 Therefore, in the presence of a functional BER, this damaged base is promptly repaired.
It was previously demonstrated that pharmacological strategies to overcome resistance of MR-deficient tumor cells to O 6 -methylating agents might rely on the inhibition of poly(ADP-ribose) polymerase (PARP). 19, 20, 22, 23 This enzyme is a component of the BER multiprotein complex and is required in sensing and signaling of DNA damage generated by monofunctional alkylating agents. 24 The inhibition of PARP is likely to hamper the completion of the BER-mediated repair process, which occurs after the methylated base has been removed by the 3-methylpurine glycosylase.
The killing effect, deriving from interruption of BERmediated repair process of N-methylpurines, is already evident during the first round of cell division. 20 In contrast, cytotoxicity induced by MR-mediated processing of O 6 methylguanine occurs during the second cycle of DNA replication. 18 These observations suggested that the drug combination of a methylating agent with a PARP inhibitor might be also useful for tumors with low proliferation rate. At this regard, it has to be noted that the poor response of solid tumors to chemotherapy is often related to the scarce proliferation of the majority of cells. In fact, cells in the G 0 / G 1 phase of the cell cycle are usually resistant to antineoplastic agents that require DNA synthesis to provoke DNA damage.
The aim of the present study is to investigate whether transduction of wild-type p53, mediated by adenovirus vector (Ad-p53), might increase susceptibility of MRdeficient tumor cells to TZM, alone or combined with PARP inhibitor. Moreover, it was also explored whether neoplastic cells, subjected to growth arrest by p53 transduction, might be still susceptible to the cytotoxic effects of the methylating agent.
The results provided evidence for the first time that Adp53 strongly enhanced the susceptibility of MR-deficient tumor cell lines, to TZM, alone or combined with PARP inhibitor. Moreover, the results indicated that TZM associated with a PARP inhibitor was markedly cytotoxic even in tumor cells that, after Ad-p53 infection, failed to proliferate.
Results
Adenovirus-mediated p53 expression in p53-null leukemic Jurkat cells increases cytotoxicity induced by TZM, alone or combined with PARP inhibitor p53-null leukemic Jurkat cells were transduced in vitro with Ad-p53 at a multiplicity of infection (MOI) of 80. The expression of p53 and growth kinetics of control or Ad-p53 infected cells were evaluated. The results of Western blot analysis, illustrated in Figure 1A , show that p53 protein could be detected only in Ad-p53 infected cells 1 day after infection. Wild-type p53 expression reached the peak 2 days after virus exposure and then gradually declined. Cell growth analysis showed a significant reduction in the growth rate of Ad-p53 infected cells with respect to controls (P50.01; Figure 1B) . No significant differences in cell growth kinetics were found between uninfected or Ad-beta-galactosidase (Ad-beta-Gal) infected control cells ( Figure 1B ).
Morphological and flow cytometry analysis of apoptosis in Ad-p53 infected cells evidenced only a limited percentage of cells undergoing apoptosis at all time points (57%), comparable to that detected in controls.
Control Ad-beta-Gal or Ad-p53 infected cells were treated with TZM, alone or combined with the PARP inhibitor 3-aminobenzamide (3-AB), 1 day after virus exposure. The kinetics of appearance and the extent of growth inhibition induced by the drugs are illustrated in Figure 2 . Treatment with the methylating agent showed marginal or no antitumor activity against Ad-beta-Gal infected Jurkat cells (Figure 2A ). In contrast, TZM (125 and 250 mM) significantly reduced the growth of p53 expressing cells after 3 and 4 days of culture (P50.01; Figure 2B ). Combined treatment with TZM+3-AB significantly inhibited cell proliferation of Ad-beta-Gal cells at 125 or 250 mM TZM (P50.01; Figure 2C ). However, drugtreated cells retained proliferative potential, since cultures subjected to TZM+3-AB started again to proliferate 2 ± 3 days after drug exposure ( Figure 2C ). In p53 transduced cells the PARP inhibitor augmented the cytotoxicity afforded by TZM used as a single agent (P50.01; Figure 2D ). In this case, however, p53 expressing cells were unable to recover the damage induced by the drug combination, at least at the two highest TZM concentrations ( Figure 2D ). In all experimental conditions, 3-AB alone was found to be essentially inactive against Jurkat cells (Figure 2 ). Flow cytometry analysis of sub-diploid DNA content ( Figure 3A ,B) indicated that p53 expression markedly potentiated the apoptotic effect of TZM+3-AB combination.
The expression of p53 was investigated in drug-treated cells 1 day after drug exposure (i.e. 2 days after Ad infection). Western blot analysis showed no substantial differences in p53 expression between untreated or drug treated groups ( Figure 3C ).
To examine whether Ad infection and/or drug treatment might trigger p21 induction, we determined p21 protein levels by Western blotting in untreated and drug treated Ad infected cells. The results, illustrated in Figure 3C , show a slight induction of p21 in Ad-p53 cells 1 day after infection, that paralleled the expression of the p53 protein. The level of p21 protein increased in response to p53 transduction after 2 days in either treated or untreated groups. It should be noted that at this time point the level of p21 expression in cells exposed to 250 mM TZM+3-AB was twofold higher than that of 3-AB treated control. No induction of p21 protein was detected in Ad-beta-Gal infected cells ( Figure 3C ).
Next, we investigated whether Ad-p53 infection, alone or combined with drug treatment, was associated with changes in the cell distribution through the different phases of cell cycle. Flow cytometry analysis showed that Ad-p53 infected samples did not show any substantial difference in the cell cycle distribution with respect to beta-Gal or uninfected controls (data not shown). In contrast, in Adp53 infected cells the association of 3-AB and 250 mM TZM induced a progressive increase of cells in the G 1 phase, after 3 days of culture (2 ± 3-fold increase with respect to day 1). Conversely, combined treatment with TZM+3-AB in Ad-beta-Gal infected cells resulted in cell accumulation in the G 2 /M phase (percentage of cells in G 2 /M phase: 40+9 at 250 mM; untreated or 3-AB treated controls; 7+2, at day 2). However, this cell cycle modification was transient, since after 3 days of culture, cells recycled back into G 1 .
In both Ad-beta-Gal and Ad-p53 infected cells, treatment with TZM did not induce any substantial change of cell cycle profiles with respect to untreated controls (data not shown).
Adenovirus-mediated p53 expression in colon carcinoma HCT-15 cells, that express a mutated form of p53, increases cytotoxicity induced by TZM, alone or combined with PARP inhibitor
The influence of p53 expression on cell growth and chemosensitivity to TZM, alone or in the presence of PARP Expression of p53 on day 1 post-infection, in HCT-15 cells was higher in cells infected at a MOI of 80 as compared to control cells endowed with a mutated form of p53 ( Figure 4B ). When HCT-15 cells were transduced at a MOI of 2.5, a less pronounced increase in wild-type p53 levels could be detected ( Figure 4B ). In spite of the limited p53 expression, the growth rate of Ad-p53 infected cells was markedly reduced with respect to that of beta-Gal control ( Figure 4A ). Ad-p53 infection at MOI of 5 and 10 induced a growth inhibition similar to that provoked by infection at a MOI of 2.5, whereas infection at a MOI of 40 was slightly less cytotoxic than 80 MOI (data not shown).
On the basis of these results, to investigate the influence of p53 expression on sensitivity of HCT-15 cells to cytotoxicity induced by the agents under study, Ad infection was performed at MOIs of 2.5 and 80, which markedly differed in their effects on cell growth. Ad-betaGal or Ad-p53 infected cells were treated with the drugs, 1 day after virus exposure ( Figure 5 ). Drug treatment of HCT-15 cells infected with Ad-p53 at a MOI of either 2.5 or 80, resulted in a pronounced reduction of the cell number, either when TZM was used as single agent or when it was combined with 3-AB ( Figure 5B ,C). Moreover, Ad-p53 cells, infected at a MOI of 80, and then exposed to TZM, alone or associated with 3-AB, were no longer able to proliferate during the 4 days of culture (data not shown). In contrast, in Ad-beta-Gal infected cells, only TZM+3-AB combination significantly affected cell proliferation (P50.01), even though at a lower extent than in Ad-p53 infected cells ( Figure 5A ). However, in this case drug-treated cells retained proliferative potential, since cultures started again to proliferate 2 days after drug exposure (data not shown).
A limited induction of apoptosis was observed in Ad-p53 infected cells treated with 125 mM and 250 mM TZM, alone (10+2 and 12+3%, respectively) or combined with PARP inhibitor (15+3 and 19+3%, respectively). In contrast, no apoptosis was observed in Ad-beta-Gal cells exposed to the same concentrations of the agents (55%). Analysis of the expression of p53 and p21 proteins in Ad infected cells, either untreated or drug treated, is illustrated in Figure 6A ,B. High amounts of either p53 or p21 could be detected in all Ad-p53 samples, whereas in control HCT-15 cells the monoclonal antibody used allowed immunodetection of the mutated form of the p53 protein.
Cell cycle distribution of Ad infected, untreated or drug treated cells were analyzed 1 day after drug exposure. Figure 6C shows that Ad-p53 infection induced an accumulation of the cells in the G 1 phase and a concomitant reduction of cells in S-phase. This distribution through the different phases of the cell cycle was not substantially influenced by the drug treatment ( Figure 6C ). Moreover, cells remained arrested at the G 1 phase during the following 3 days of culture (data not shown). In contrast, Ad-beta-Gal infected cells exposed to the combined treatment of TZM and 3-AB accumulated in the G 2 /M phase.
Subcellular localization of adenovirus-mediated p53 expression
In order to test whether the different effect exerted by Adp53 on cell growth of Jurkat and HCT-15 cells might be due to a distinct subcellular distribution of transduced p53, expression of the protein was assessed either in the nuclear Western blot analysis was then performed using an amount of nuclear proteins 10-fold higher than that tested in the immunoblot shown in Figure 7A . In this experimental condition, p53 could be detected also in the nuclear fraction of Ad-p53 infected Jurkat cells ( Figure  7B ). In order to test whether cells arrested in their growth are still susceptible to the cytotoxicity induced by the combination of TZM and PARP inhibitor, HCT-15 cells were exposed to the drugs 2 days after infection at a MOI of 20. In fact, in this experimental condition cells were no longer able to proliferate, although no reduction in cell number was observed ( Figure  8A ). It was then investigated whether any DNA synthesis could be detected in Ad-p53 infected HCT-15 cells at the moment of drug exposure, by means of 5-bromodeoxyuridine (5-BrdU) incorporation. The results of a representative experiment are illustrated in Figure 8B and show that a limited percentage of cells in the S-phase was observed 1 day after infection, whereas most of the cells accumulated in G 1 phase. Moreover, on day 2 post-infection virtually no incorporation of 5-BrdU was detected. In addition, in Ad-p53 infected cells a marked and progressive induction of p21 was observed ( Figure 8C ). Altogether, these data indicated that the growth of HCT-15 cells was completely arrested 2 days after exposure to Ad-p53 at a MOI of 20. Cells were then exposed to 250 mM TZM, alone or in combination with 3-AB, and analyzed for cell number 1 day after treatment. The results are expressed as percentage of cell number reduction of drug treated cells with respect to untreated controls. Two antitumor agents, that are used for treatment of colon carcinoma, were also tested. In particular, raltitrexed, a direct inhibitor of thymidylate synthase (TS) was used as a control of an anticancer agent that requires active DNA synthesis in order to be effective. Moreover, 5-fluorouracil (5-FU), which indirectly inhibits TS but also affects RNA function, was tested. The results, illustrated in Figure 9 , show that TZM combined with the PARP inhibitor markedly reduce the number of Adp53 cells. In contrast, raltitrexed (100 nM) induced a reduction of cell growth only in Ad-beta-Gal controls, whereas it did not have any effect in Ad-p53 cells. On the other hand, induction of wild-type p53 potentiated the cytotoxicity of 5-FU (10 mM) (Figure 9 ).
Adenovirus-mediated p53 expression in tumor cells bearing wild-type p53 gene, increases cytotoxicity induced by TZM, alone or combined with PARP inhibitor Leukemic MT-1 or colon carcinoma HCT-116 cells, that possess wild-type p53 gene and a functional defect in MR function, were transduced in vitro with Ad-p53 at a MOI of 80. The kinetics of p53 expression during 3 days of culture was evaluated. The results of Western blot analysis, illustrated in Figure 10 , show that p53 protein could be detected only in Adp53 infected cells. In MT-1 cells the level of p53 expression reached the peak 1 day after virus exposure and thereafter declined, unlike in HCT-116 where the transduced protein was overexpressed at all time points tested.
Cell growth analysis in MT-1 cells showed a significant reduction in the growth rate of Ad-p53 infected cells with respect to controls (P50.01, Figure 11 ). Treatment with the methylating agent induced limited cytotoxic activity against Ad-beat-Gal infected MT-1 cells ( Figure 11A ). In contrast, TZM (125 and 250 mM) significantly reduced the growth of Ad-p53 infected cells after 3 and 4 days of culture (P50.01; Figure 11B ). Treatment of Ad-beta-Gal cells with 3-AB significantly (P50.01) increased cytotoxicity Figure 11C ). In contrast, p53 expressing cells were unable to recover the damage induced by the drug combination, at least at the two highest TZM concentrations ( Figure 11D ).
Flow cytometry analysis of sub-diploid DNA content in Ad-p53 infected cells evidenced only a limited percentage of cells undergoing apoptosis at all time points (54%), comparable to that detected in controls. Moreover, p53 transduction significantly (P50.01) potentiated the apoptotic effect of TZM+3-AB combination (data not shown).
Ad-p53 infection of HCT-116 resulted in growth arrest. Nonetheless, Ad-p53 infected cells were susceptible to cytotoxicity induced by TZM, either used as single agent or combined with 3-AB ( Figure 12) . Noteworthy, the combination of Ad-p53 infection and chemotherapy was more cytotoxic with respect to pharmacological treatment (P50.01). In Ad-beta-Gal infected cells, although 3-AB potentiated the antitumor effect of TZM, growth inhibition was only transient (Figure 12 ).
In the case of HCT-116, p53 overexpression significantly potentiated (2 ± 3-fold increase) the apoptotic effect of either TZM or TZM+3-AB combination.
Discussion
Lack of p53 and MR function and scarce tumor cell proliferation are generally associated with tumor cell phenotype of resistance to antineoplastic agents. In the present study we demonstrated, for the first time, that wildtype p53 transduction enhances chemosensitivity of MRdeficient tumor cells to the methylating compound TZM, either used as single agent or combined with PARP inhibitor. Moreover, it was pointed out that this drug combination is also highly cytotoxic in the absence of active DNA synthesis and regardless of the cellular p53 status.
In the model system that we used, Ad-p53 infection of leukemic cells was associated with a transient growth inhibitory effect. Unlikely, p53 overexpression in colon carcinoma cells completely suppressed cell growth. In the cell lines tested, however, Ad-p53 infection did not induce apoptosis. These data are in accordance with previous studies with different tumors, including colon carcinoma. 25 ± 27 Nevertheless, other reports showed that overexpression of wild-type p53 induced apoptosis. 28 ± 30 Overall, these results suggested that a variety of tumor types might present different responses to high levels of p53 expression. Moreover, in the case of leukemic cells, it cannot be excluded that upon Ad infection not all the cells were infected by the virus or adequately expressed the transgene, since leukemic cells have been described to be quite resistant to Ad infection. 31, 32 Actually, in Jurkat cells, most of the ectopic p53 protein was confined in the cytoplasmic compartment, whereas in HCT-15 cells a high level of the transduced protein was observed also in the nuclei.
In tumor cell lines p53 expression was accompanied by transactivation of p21, which is known to mediate G 1 cell cycle arrest by causing inhibition of the cyclin-dependent kinase activity required for the progression from the G 1 to the S-phase. 33, 34 Nonetheless, Ad-p53 infection induced a marked G 1 and growth arrest only in colon carcinoma cells.
Taking into account the possible limitations of Ad-p53 infection, it was of interest to investigate whether the combination of gene therapy based on p53 transduction with chemotherapy might result in enhanced cytotoxicity. In this regard, it has to be noted that the tumor cell lines selected for the study are MR-deficient and therefore represent a model of resistance to O 6 -methylating agents. Inhibition of BER process, that is involved in the repair of adducts different from O 6 -methylguanine, has been recently demonstrated to represent a valuable strategy to sensitize MR-deficient tumor cells to methylating agents. 20, 22, 23 In fact, even though O 6 -methylguanine has been, until now, the best studied cytotoxic DNA lesion, it is neither the most abundant nor the only adduct generated by these compounds. 21 In the absence of MR function, interruption of BER-mediated repair process of N-methyl-purine adducts, by means of PARP inhibition, might play a crucial role in the cytotoxicity induced by TZM.
Treatment with TZM+PARP inhibitor of MR-deficient leukemic or colon cancer cells, bearing wild-type p53, is followed by the induction of p53 and p21 proteins (L Tentori and G Graziani, unpublished observation). These observa- tions suggested that the DNA damage deriving from interruption of the repair of N-methyl-purine adducts triggers the p53-dependent machinery. The results of the present study indicated that Ad-p53 infection markedly enhanced tumor cell susceptibility to the combination of the methylating agent TZM with a PARP inhibitor. In particular, when Ad-p53 infected tumor cells were exposed to the drug combination, they were no longer able to proliferate and accumulated in the G 1 phase of cell cycle. Interestingly, in the case of HCT-15 line, cells were extremely sensitive to growth inhibition provoked by ectopic expression of p53. Therefore, potentiation of drug-mediated cytotoxicity was particularly evident when cells were infected at MOI concentrations (2.5 and 20 MOI) devoid of cytotoxic effects. It is worth noting that overexpression of p53 enhanced also the susceptibility of MR-deficient cells to the treatment with TZM used as single agent. It can be speculated that in experimental conditions of high levels of p53 expression, the repair of adducts different from O 6 -methylguanine might be impaired.
The observation that, in tumor cells bearing an intact p53 gene, drug treatment induced growth arrest only when cells were previously infected with Ad-p53, suggests that Ad-p53 infection does not represent a mere replacement of wildtype function. It can be speculated that the presence of high levels of p53 protein, before exposure to the drugs, might sensitize cells to DNA damage and promote apoptosis.
The clinical interest in methylating agents, such as dacarbazine or TZM, is related to their activity against tumors of different origin. Dacarbazine is the drug of choice for the treatment of melanoma, and is also used for the treatment of sarcomas and lymphomas. In addition, it has shown activity in acute leukemias, relapsed or refractory to standard chemotherapy. 35 Of interest, phase II and III trials demonstrated that TZM is effective against recurrent glioma, and melanoma. 36 ± 39 Although promising, the antitumor activity of methylating agents is far from being resolved. Poor responsiveness of solid tumors to cancer chemotherapy is mainly related to the fact that most of the cells are in a plateau growth phase, with only a small fraction of actively proliferating cells. Moreover, it has been shown that, in some cases, Adp53 infection did not result in enhanced lethal effect of the antitumor agent, when cells were exposed to the drug after infection. In fact, in the case of chloroethylating agents, tumor cells were less susceptible to the sequence Ad-p53?drug than to the reverse sequence, which instead induced a marked growth inhibitory effect. 40 These observations were related to the fact that p53 overexpression would induce G 1 arrest, thus hampering the DNA damage induced by alkylating agents that require DNA synthesis in order to cause cell death. Moreover, p53 overexpression, when achieved before drug treatment, did not result in increased cell susceptibility to other antineoplastic agents such as the mitosis specific agent taxol. 41 On the basis of these observations, it has been investigated whether MR-deficient and non-proliferating p53 expressing cells could still be sensitized to the treatment with TZM, used as single agent or in combination with PARP inhibitor. The results of the present study indicated that the drug combination of TZM and PARP inhibitor was still highly effective, even in the absence of DNA synthesis. Thus, it is conceivable that cytotoxicity deriving from interruption of the repair of adducts different from O 6 -methylguanine does not require cell proliferation. In contrast, cytotoxicity deriving from the processing of O 6 -methylguanine, in MR-proficient cells, occurs only during the second cycle of DNA replication, that follows adduct generation. 18 When growth arrested cells were exposed to TS inhibitor, this agent lost the ability to kill tumor cells. In this case, lack of antitumor activity might be attributed to the fact that only cells that actively synthesize DNA can be damaged upon reduction of the availability of thymidilic nucleotides. In contrast, 5-FU, that either acts as an indirect inhibitor of TS or affects RNA functions, was still active in non-proliferating cells. Actually, wild-type p53 expression increased 5-FU cytotoxic activity, in accordance with previous studies performed using different model systems. 41 ± 43 At present, adenovirus-mediated p53 gene therapy for cancer is currently undergoing phase I/II clinical trials. These studies are being conducted with the aim of utilizing Ad-p53, by intratumoral injection, as a surgical adjuvant in patients with advanced head and neck cancer 44 and nonsmall-cell lung carcinoma. 45 Moreover, Ad-p53 has also been delivered by intrahepatic artery route of administration for the treatment of liver metastasis of colorectal cancer. 46 However, the results of the present study raise some concerns on the use of Ad-p53 as single agent, taking into account that adenovirus infection might not be targeted to the whole cell population or result in persistent growth arrest. In addition, a number of preclinical studies suggested that Ad-p53 gene therapy should be combined to chemotherapy or radiotherapy, because enhanced antitumor activity has been observed in different model systems. 25, 27, 41, 42, 47 In conclusion the results of the present study propose a future strategy based on Ad-p53 infection in combination with either TZM or TZM+PARP inhibitor, especially in the case of drug resistant tumors.
Materials and Methods

Cells and cell culture
All cell lines were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA), with the exception of the human lymphoblastoid MT-1, 48 that was a generous gift from WG Thilly (Massachusetts Institute of Technology, Cambridge, MA, USA). The T-lymphoblastic leukemia Jurkat cell line is p53-null, 49 whereas MT-1 is capable of inducing p53 upon treatment with DNA damaging agents. 18 The colon carcinoma HCT-15 cell line expresses a mutated form of p53 50 whereas HCT-116 possesses a wild-type form of p53. 51 All cell lines listed above are MR-deficient.
48,52 ± 55
The lymphoblast-like Raji and the colon carcinoma HT-29 cell lines, both expressing a mutated form of p53, 56, 57 were used as controls in Western blot analysis. Cells were cultured at 378C in a 5% CO 2 humidified atmosphere in RPMI-1640 (Gibco, Paisley, Scotland, UK), supplemented with 10% heat inactivated (568C, 30 min) fetal calf serum (Gibco), 2 mM L-glutamine, and antibiotics (Flow Laboratories, McLean, VA, USA). 
Drugs
Adenovirus vectors and infection
For this study two replication-deficient, recombinant adenovirus vectors were used. AdCMV.p53 (Ad-p53), 33 that contains the human wild-type p53 cDNA driven by the CMV promoter, was a generous gift from Dr. B Vogelstein (Johns Hopkins University, Baltimore, MD, USA). As a control vector, AdCMV.NLS beta-Gal (Ad-beta-Gal), that expresses the beta-galactosidase gene, was used. 33 This vector, that expresses nuclear localized beta-galactosidase, was obtained from Dr. MC Capogrossi (`Istituto Dermopatico dell'Immacolata', Rome, Italy). The virus titers were determined by plaque formation following infection of human primary embryonal cells of kidney 293 line. MOI was defined as the ratio of the total number of plaque-forming units used in a particular infection per total number of cells to be infected. Jurkat and HCT-15 cells were infected with Ad equivalent to a MOI of 2.5, 20 or 80, as specified. Tumor cells, in the exponential phase of growth, were infected, by adding Ad in 1 ml RPMI per 1610 6 cells. After 1 h, the medium was replaced with fresh medium and cells were cultured at the concentration of 2610 5 cells/ml for an additional 4 days. At daily intervals, cells were counted and collected for flow cytometry or Western-blot analysis.
Drug treatment and cell growth evaluation
Drug treatment was performed 1 day after Ad exposure. In selected experiments with HCT-15 line, cells were exposed to the drugs 2 days after infection at a MOI of 20. Cells were seeded in culture flasks (Falcon, Becton & Dickinson Labware, Oxnard, CA, USA) at the a concentration of 2610 5 cells/ml. TZM was added to the culture medium at final concentrations ranging between 62.5 and 250 mM. Inhibition of PARP was obtained by treating the cells with 4 mM 3-AB, a concentration that has been described as abrogating PARP activity. 58 The PARP inhibitor was added to the cultures immediately before TZM treatment. Cells were then incubated at 378C for 4 days and cell growth was evaluated in terms of count of viable cells, every 24 h. Cells were manually counted in quadruplicate using a haemocytometer, and cell visibility was determined by trypan blue exclusion test.
Statistical analysis
The results are presented as mean values of quadruplicate counts+standard error (S.E.). In the case of percentage values, means and the relative S.E. were calculated following angular transformation of the data. Statistical analysis was performed by Student's t-test.
Western blotting
Cell lysates and samples for electrophoresis were prepared as previously described. 20 Eighty mg of protein per sample were electrophoresed in 12% SDS-polyacrylamide mini-gels. Afterwards, proteins were transferred to nitrocellulose membranes (Schleicher & Schuell, Keene, NH). Equal protein loading was visualized by Ponceau S staining. Filters were blocked with blocking buffer (Boehringer Mannheim) and incubated with monoclonal antibodies directed against p53 (clone PAb1801), p21 WAF1/CIP1 (p21, clone EA10) (Oncogene, Cambridge, MA, USA) or with antibody against actin (Sigma). Immunecomplexes were visualized using a chemiluminescence kit (Amersham International Plc, Amersham, UK), according to the manufacturer's instructions. Filters were exposed to X-OMAT AR autoradiographic films (Kodak, Rochester, NY, USA) for 10 ± 45 s, depending on the intensity of the signal. Bidimensional densitometry of the blots was performed using an imaging densitometer, GS-670 (BioRad, Richmond, CA, USA) and optical densities (O.D.) were expressed as arbitrary units.
nyl fluoride hydrochloride and disrupted by 30 strokes in a tight fitting dounce homogenizer until nuclei were released as observed by phase microscopy. After low speed centrifugation (6006g), the nuclear fraction was collected and the supernatant, corresponding to the soluble and particulate fractions of the cytoplasm, was lysed using 16 buffer (50 mM Tris HCl pH 7.5, 2 mM EGTA, 10 mM dithiothreitol, 1% Triton X-100 or 46, buffer, respectively.
Assessment of apoptosis and cell cycle analysis
Cells from cultures were washed with PBS and fixed in 70% ethanol at 7208C for 18 h. The centrifuged pellets were resuspended in 1 ml of hyptotonic solution containing propidium iodide (PI) (50 mg/ml), 0.1% sodium citrate, 0.1% Triton-X, and RNase (10 mg/ml) (PI solution). Cells were incubated in the dark, at 378C for 15 min. Data collection was gated utilizing forward light scatter and side light scatter to exclude cell debris and cell aggregates. The PI fluorescence was measured on a linear scale using a FACSscan flow cytometer (Becton and Dickinson, San Jose, CA, USA). Apoptotic cells, are represented by a broad hypodiploid peak (sub-G1), which is easily distinguishable from the narrow peak of cells with diploid DNA content in the red fluorescence channel. All data were recorded and analyzed using Lysis II software. For cell cycle analysis the cell-fit software was used (Becton and Dickinson).
Apoptosis was always confirmed by morphological analysis of nuclear fragmentation of cells fixed with methanol/acetic acid (3/1) and then stained with 5% Giemsa in phosphate buffer. The results of morphological analysis were always comparable to those obtained by flow cytometry (data not shown).
Evaluation of 5-BrdU incorporation
Ad-beta-Gal and Ad-p53 infected cells were cultured for 2 days and pulsed with 10 mM 5-BrdU (Sigma) 1 h before harvesting. Ethanol fixed cells were washed with PBS, resuspended in 2 ml of 2 M HCl, and incubated at room temperature for 30 min. Cells were then centrifuged, resuspended in 2 ml of 0.1 M Na 2 B 4 O 7 , pH 8.5 (to neutralize acidity) and washed with PBS containing 0.5% (v/v) Tween 20 and 1% (w/v) bovine serum albumine. The cell pellets were resuspended in 0.1 ml of PBS containing 0.4 mg of anti-5-BrdU (Boehringer Mannheim, Mannheim, Germany) and were maintained at room temperature in the dark for 30 min. They were then washed and stained with 0.1 ml of diluted (1/50) FITC-labeled (Fab')2 rabbit antimouse IgG (H+L chains) (Dako, Glostrup, Denmark). Negative controls were represented by cell samples stained with FITC-labeled rabbit anti-mouse IgG only. After 30 min incubation, cells were washed, resuspended in 1 ml of PI solution and then incubated at 378C for 10 min. Cell samples were analyzed for green (FITC, indicating 5-BrdU incorporation) and red (PI, indicating DNA content) fluorescence, using a FACScan flow cytometer. The number of cells in each phase of cell cycle was analyzed using the Lysis II software. The results were displayed as representative two-dimensional frequency dot plots of green versus red fluorescence.
